CorMedix Inc. (CRMD) CFO Robert W. Cook Acquires 52,083 Shares

CorMedix Inc. (NYSEAMERICAN:CRMD) CFO Robert W. Cook bought 52,083 shares of the company’s stock in a transaction that occurred on Tuesday, December 12th. The shares were bought at an average price of $0.48 per share, with a total value of $24,999.84. Following the transaction, the chief financial officer now owns 102,083 shares of the company’s stock, valued at approximately $48,999.84. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of CorMedix Inc. (CRMD) traded down $0.01 during trading hours on Thursday, hitting $0.56. 729,869 shares of the company were exchanged, compared to its average volume of 678,664. CorMedix Inc. has a 12-month low of $0.32 and a 12-month high of $2.48.

Hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in CorMedix by 3.0% during the second quarter. Vanguard Group Inc. now owns 1,208,894 shares of the biotechnology company’s stock valued at $518,000 after purchasing an additional 35,148 shares during the last quarter. Susquehanna International Group LLP lifted its position in CorMedix by 11,785.4% during the second quarter. Susquehanna International Group LLP now owns 2,067,973 shares of the biotechnology company’s stock valued at $886,000 after purchasing an additional 2,085,670 shares during the last quarter. Elliott Management Corp lifted its position in CorMedix by 177.8% during the second quarter. Elliott Management Corp now owns 4,166,868 shares of the biotechnology company’s stock valued at $1,785,000 after purchasing an additional 2,666,668 shares during the last quarter. Finally, Sabby Management LLC bought a new position in CorMedix during the second quarter valued at $1,818,000.

A number of equities analysts recently weighed in on the stock. Zacks Investment Research lowered shares of CorMedix from a “buy” rating to a “hold” rating in a research report on Friday, September 22nd. HC Wainwright restated a “buy” rating and set a $4.00 target price (up previously from $3.00) on shares of CorMedix in a research report on Monday, September 25th.

WARNING: This story was reported by American Banking News and is owned by of American Banking News. If you are reading this story on another website, it was copied illegally and reposted in violation of US and international copyright & trademark legislation. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/12/14/cormedix-inc-crmd-cfo-robert-w-cook-acquires-52083-shares.html.

CorMedix Company Profile

CorMedix Inc is a commercial pharmaceutical and medical device company. The Company in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications.

Insider Buying and Selling by Quarter for CorMedix (NYSEAMERICAN:CRMD)

Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply